Rezum versus prostatic artery embolization for relieving urinary symptoms from BPH
Official title: Comparison Between Water Vapor Thermal Therapy and Prostatic Artery Embolization in Treatment of Benign Prostatic Hyperplasia
Run by Ain Shams University · NCT07416227 · Data updated 2026-11-12
This study will test whether Rezum (water vapor therapy) or prostatic artery embolization works better at reducing bothersome urinary symptoms in men with moderate-to-severe BPH.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years and up |
| Sex | Men only |
| Enrollment | 30 (estimated) |
| Sponsor | Ain Shams University Academic / other |
| Locations | 1 site (Cairo, Abbassia) |
| Status | Recruiting |
| Started | October 1, 2025 |
| Main results expected | October 1, 2027 |
| Study ends | October 1, 2027 |
| Registry record updated | February 18, 2026 |
| Trial ID | NCT07416227 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are men aged 50 or older with IPSS ≥13, prostate volume 30–80 mL, Qmax ≤15 mL/sec when relevant, and symptoms not controlled by medication.
✕Probably not a fit
Patients with suspected or prior prostate cancer, previous prostate surgery or minimally invasive BPH procedures, neurological bladder dysfunction, active urinary tract infection, or prostate sizes outside the 30–80 mL range are unlikely to be eligible or to benefit from the study interventions.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized controlled trial will enroll at least 30 men with moderate-to-severe LUTS from BPH and randomize them 1:1 to receive Rezum or prostatic artery embolization using a closed-envelope system. The primary outcome is change in International Prostate Symptom Score (IPSS) at six months, with secondary outcomes including post-void residual, maximum urinary flow rate (Qmax), quality of life measures, and validated sexual function questionnaires. Participants will undergo baseline history, physical examination, pelvic ultrasound and scheduled follow-up visits to measure symptoms and urinary function. The trial is single-center at Ain Shams University in Cairo and will recruit over a two-year period.
Why it matters
Potential benefit: If successful, the comparison could identify a minimally invasive option that improves urinary symptoms while preserving ejaculatory and overall sexual function.
How similar studies have gone: Separate studies have shown that Rezum improves symptoms and preserves sexual function, and that prostatic artery embolization can reduce prostate size and LUTS, but randomized head-to-head comparisons between these two approaches are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥50 years. * IPSS ≥13. * Prostate volume between 30-80 mL. * Maximum urinary flow rate (Qmax) ≤15 mL/sec in patients with voiding LUTs. * Patients not responding to medical treatment. Exclusion Criteria: * History or suspicion of prostate cancer. * Previous prostate surgery or minimally invasive BPH intervention. * Neurological bladder dysfunction. * Active urinary tract infection.
Where it's running
-
Ain Shams University
Cairo, Abbassia, Egypt Recruiting
Study contacts
- Study coordinator: Seif AbdElmomen Yosef, MBBCh, MSc Faculty of Medicine
- Email: siefabdelmomen@gmail.com
- Phone: 01093390291
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing two surgical methods for treating enlarged prostate
This study is testing two different surgical methods for treating an enlarged prostate to see which one is safer and more effective for men with urinary problems.
-
NAVA use in preterm neonates with respiratory distress syndrome
This trial tests whether neurally adjusted ventilatory assist (NAVA) helps preterm babies with respiratory distress syndrome breathe more easily than conventional ventilation.
-
Ruta C and Vitamin C in Sepsis: Adding antioxidants to standard care
This trial tests whether adding Ruta C (rutin plus vitamin C) or vitamin C alone to standard sepsis treatment helps adults in the ICU stay shorter and recover better.
-
Left DLPFC rTMS vs iTBS for emotional dysregulation, impulsivity, and NSSI in Borderline Personality Disorder
This trial tests whether high-frequency rTMS or intermittent theta-burst stimulation over the left DLPFC can help reduce emotional instability, impulsivity, and non-suicidal self-injury in adults with Borderline Personality Disorder.
-
Trimetazidine as an extra therapy for aluminum phosphide poisoning
In this pilot trial, adults with acute aluminum phosphide poisoning receive standard care plus trimetazidine to see if it helps save lives and improve recovery.
-
Comparing 3D Face Scans with Manual Measurements for Vertical Dimension in People with Complete Dentures
This study tests whether a 3D face scan can reliably measure the vertical dimension of occlusion in people who wear complete dentures, compared with traditional manual methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.